Immunotherapy in SCLC: FAQ on Current Best Practice and Emerging Therapeutic Strategies

In this episode, Anna F. Farago, MD, PhD, and Taofeek K. Owonikoko, MD, PhD, answer questions  focused on the topic of current and evolving use of immunotherapy in patients with advanced small-cell lung cancer with topics including:

• Selecting between atezolizumab and durvalumab in the frontline setting
• Integration of lurbinectedin, a novel anticancer drug that was recently approved for the treatment of relapsed SCLC after platinum-based chemotherapy, into patient care
• Which patients should receive salvage therapy with an immune checkpoint inhibitor in the third-line setting
• Management of brain metastases in patients with advanced SCLC

Presenters:

Anna F. Farago, MD, PhD
Assistant Professor of Medicine
Department of Medicine
Harvard Medical School
Assistant in Medicine
Division of Hematology/Oncology
Department of Medicine
Massachusetts General Hospital
Boston, Massachusetts 

Taofeek K. Owonikoko, MD, PhD
Professor
Department of Hematology and 
Medical Oncology
Co-Leader, Thoracic Oncology
Emory University
Atlanta, Georgia

Content based on an online CME program supported by educational grants from Genentech, a member of the Roche Group, and Merck Sharp & Dohme Corp. 

Link to full program, including associated downloadable slidesets:  https://bit.ly/3aTzthZ

Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.